Free tool
FAERS Monitor: Sensorcaine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018304 or its brand name (Sensorcaine, Bupivacaine Hydrochloride, Epinephrine Bitartrate). Reports on generic versions are filed under their own applications.
Reports
2,545
Serious
1,664
65% of reports
Hospitalization
649
Death reported
231
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective653
- anaesthetic complication215
- musculoskeletal pain202
- maternal exposure during pregnancy196
- off label use180
- hypoaesthesia152
- hypotension128
- condition aggravated126
- joint injury126
- dyspnoea122
- hypertension118
- headache114
- fatigue99
- dizziness98
- joint range of motion decreased98
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 20 |
| 2005 | 10 |
| 2006 | 30 |
| 2007 | 14 |
| 2008 | 28 |
| 2009 | 158 |
| 2010 | 78 |
| 2011 | 39 |
| 2012 | 37 |
| 2013 | 37 |
| 2014 | 28 |
| 2015 | 106 |
| 2016 | 283 |
| 2017 | 35 |
| 2018 | 78 |
| 2019 | 88 |
| 2020 | 107 |
| 2021 | 138 |
| 2022 | 255 |
| 2023 | 188 |
| 2024 | 275 |
| 2025 | 302 |
| 2026 | 211 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,614 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anaesthetic complicationSignal | 215 | 719.1 | 629.1 | 141,210 |
| joint range of motion decreasedSignal | 98 | 60.8 | 50.0 | 5,667 |
| joint injurySignal | 126 | 49.0 | 41.3 | 5,852 |
| musculoskeletal painSignal | 202 | 32.0 | 28.0 | 6,024 |
| maternal exposure during pregnancySignal | 196 | 18.2 | 15.9 | 3,178 |
| hypoaesthesiaSignal | 152 | 8.4 | 7.2 | 990 |
| hypotensionSignal | 128 | 5.3 | 4.5 | 443 |
| hypertensionSignal | 118 | 4.6 | 3.9 | 333 |
| drug ineffectiveSignal | 653 | 4.1 | 3.8 | 1,626 |
| condition aggravatedSignal | 126 | 3.4 | 2.9 | 217 |
| dyspnoea | 122 | 1.8 | 1.5 | 42 |
| off label use | 180 | 1.7 | 1.5 | 53 |
| dizziness | 98 | 1.6 | 1.3 | 23 |
| headache | 114 | 1.5 | 1.3 | 19 |
| fatigue | 99 | 1.1 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.